RhumbLine Advisers’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-68,399
| Closed | -$308K | – | 4193 |
|
|
2025
Q2 | $308K | Buy |
68,399
+14,490
| +27% | +$65.1K | ﹤0.01% | 2969 |
|
|
2025
Q1 | $239K | Buy |
53,909
+2,457
| +5% | +$14.3K | ﹤0.01% | 3019 |
|
|
2024
Q4 | $403K | Sell |
51,452
-863
| -2% | -$10.5K | ﹤0.01% | 2806 |
|
|
2024
Q3 | $688K | Sell |
52,315
-2,053
| -4% | -$26K | ﹤0.01% | 2494 |
|
|
2024
Q2 | $657K | Sell |
54,368
-856
| -2% | -$11.6K | ﹤0.01% | 2474 |
|
|
2024
Q1 | $898K | Buy |
55,224
+1,211
| +2% | +$16.3K | ﹤0.01% | 2309 |
|
|
2023
Q4 | $368K | Sell |
54,013
-874
| -2% | -$5.05K | ﹤0.01% | 2845 |
|
|
2023
Q3 | $299K | Buy |
54,887
+2,098
| +4% | +$12.2K | ﹤0.01% | 2937 |
|
|
2023
Q2 | $358K | Buy |
52,789
+4,155
| +9% | +$31.1K | ﹤0.01% | 2893 |
|
|
2023
Q1 | $244K | Sell |
48,634
-115
| -0.2% | -$470 | ﹤0.01% | 2684 |
|
|
2022
Q4 | $238K | Buy |
48,749
+1,944
| +4% | +$14.1K | ﹤0.01% | 2746 |
|
|
2022
Q3 | $675K | Buy |
46,805
+3,294
| +8% | +$54.5K | ﹤0.01% | 2356 |
|
|
2022
Q2 | $658K | Buy |
43,511
+7,419
| +21% | +$86.6K | ﹤0.01% | 2343 |
|
|
2022
Q1 | $429K | Sell |
36,092
-325
| -0.9% | -$3.34K | ﹤0.01% | 2489 |
|
|
2021
Q4 | $590K | Sell |
36,417
-605
| -2% | -$12.9K | ﹤0.01% | 2447 |
|
|
2021
Q3 | $1.06M | Buy |
37,022
+2,001
| +6% | +$63.1K | ﹤0.01% | 2206 |
|
|
2021
Q2 | $1.18M | Sell |
35,021
-675
| -2% | -$21.7K | ﹤0.01% | 2168 |
|
|
2021
Q1 | $1.08M | Sell |
35,696
-2,800
| -7% | -$115K | ﹤0.01% | 2158 |
|
|
2020
Q4 | $1.91M | Buy |
38,496
+1,941
| +5% | +$89.8K | ﹤0.01% | 1871 |
|
|
2020
Q3 | $1.4M | Sell |
36,555
-5,320
| -13% | -$212K | ﹤0.01% | 1860 |
|
|
2020
Q2 | $1.81M | Buy |
41,875
+13,827
| +49% | +$523K | ﹤0.01% | 1786 |
|
|
2020
Q1 | $732K | Buy |
28,048
+826
| +3% | +$24K | ﹤0.01% | 2014 |
|
|
2019
Q4 | $851K | Buy |
27,222
+5,169
| +23% | +$153K | ﹤0.01% | 2153 |
|
|
2019
Q3 | $575K | Buy |
22,053
+616
| +3% | +$15.7K | ﹤0.01% | 2263 |
|
|
2019
Q2 | $490K | Buy |
+21,437
| New | +$492K | ﹤0.01% | 2367 |
|
Other funds holding YMAB
RhumbLine Advisers's YMAB Position: Q3 2025 in Review
RhumbLine Advisers sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 68,399 shares — an estimated $308K sold.
RhumbLine Advisers first reported a position in YMAB in Q2 2019 and held it in 25 quarters. The position peaked at $1.91M in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- RhumbLine Advisers reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- RhumbLine Advisers sold 68,399 Y-mAbs Therapeutics shares in Q3 2025, an estimated $308K.
- RhumbLine Advisers first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 25 quarters.
- RhumbLine Advisers's Y-mAbs Therapeutics position peaked at $1.91M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.